trial

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

NCTId NCT05778591
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 40 (estimated)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2026-12-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
40 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2024-05-17
Primary completion
2026-12-01
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Buprenorphine 0.15 MG [Belbuca]

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor

Sites

1 total
Los Angeles, United States

Linked catalysts

1
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia — primary completion2026-12-01

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE2
Primary Completion Date
2026-12-01
Status
RECRUITING
relationships
The graph out of here
drug
Buprenorphine 0.15 MG [Belbuca]
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
indication
Schizophrenia
indication
Schizophrenia
indication